IOFW: The Effects of io Fibrewater Supplementation on Gut Health, Immunity and Metabolism in Overweight Adults

Sponsor
University of Roehampton (Other)
Overall Status
Recruiting
CT.gov ID
NCT05908474
Collaborator
(none)
30
1
2
5.2
5.7

Study Details

Study Description

Brief Summary

Despite availability of many alternative and conventional weight loss options, the prevalence of obesity increased from 15% in 1993 to 27 in 2015. In 2015, 68% of men and 58% of women in the UK were overweight or obese. Overweight and obesity increase the risk for comorbidities such as hypertension, dyslipidaemia, cardiovascular disease, type 2 diabetes and certain cancers. Hormonal regulation of appetite has been shown to influence body weight and body fat . Gut hormones secreted from the intestine are particularly important both in the regulation of appetite and blood glucose level, and recently the gut hormone Glucagon Like Peptide -1 (GLP-1) has been successfully targeted to treat both type 2 diabetes and obesity. Targeting the gut microbiota has been shown to influence gut hormones, in a way is likely to help treat or prevent obesity and type 2 diabetes. In past decades, considerable attention has been given to investigating the new applications of natural prebiotic polymers on gut microbiota composition. Moreover, recent trend in research indicates a bidirectional communication between the gut microbiota and the central nervous system through the microbiome-gut-brain axis (MGBA).

Therefore an in vivo intervention feeding study is proposed performed with a variety of psychological and nutritional tests aiming to compare io fibrewater with an equivalent placebo control water and also highlight both cognitive function, emotional bias and response to appetite and also metabolic profiles of the gut microbiota.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Enriched fibre water
N/A

Detailed Description

Study design: A 30-day placebo-controlled randomised trial study in overweight adults who have not been diagnosed with Diabetes.

Participants: 20 participants will be invited to take part in this study. They will be randomly assigned to treatment (n=10) or control (n=10) groups, where they will consume io Fibrewater or Volvic sugar free Lemon & Lime water for 4 weeks. Both water samples (1 bottle/day) need to be taken with the meals (lunch).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
A 30-day placebo-controlled randomised trial study in overweight adults who have not been diagnosed with DiabetesA 30-day placebo-controlled randomised trial study in overweight adults who have not been diagnosed with Diabetes
Masking:
Double (Participant, Investigator)
Primary Purpose:
Treatment
Official Title:
Preliminary Pilot Exploratory Investigations Into the Effects of io Fibrewater Supplementation on Body Composition Parameters, Blood Chemistry and Cognitive, Psychological, and Behavioural Factors in Overweight Adults
Actual Study Start Date :
Apr 25, 2023
Anticipated Primary Completion Date :
Sep 1, 2023
Anticipated Study Completion Date :
Oct 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: iowater fibre Group

This exclusive blend of scientifically substantiated ingredients has been demonstrated to contribute to the reduction of body weight and aid the sustainability of weight loss by providing a healthy, hunger-free weight management system. iofibrewater, makes fibre and gut health simple and refreshing. Each 500 ml bottle of ió fibrewater provides 20%* of your recommended daily fibre intake and 100%* of your daily prebiotic fibre intake with minimal calories and carbohydrates, making us suitable for people on a variety of diets. ió fibrewater is a functional water infused with prebiotic fibre (aka prebiotics), which leads to sub-optimal gut health and often the onset of digestive disorders. By adding more prebiotic fibre to our diet, we can quickly change the environment in our gut for the better healthy living.

Dietary Supplement: Enriched fibre water
Blend of scientifically substantiated ingredients has been demonstrated to contribute to the reduction of body weight and aid the sustainability of weight loss by providing a healthy, hunger-free weight management system. iofibrewater, makes fibre and gut health simple and refreshing. Each 500 ml bottle of ió fibrewater provides 20%* of your recommended daily fibre intake and 100%* of your daily prebiotic fibre intake with minimal calories and carbohydrates, making us suitable for people on a variety of diets. ió fibrewater is a functional water infused with prebiotic fibre (aka prebiotics), which leads to sub-optimal gut health and often the onset of digestive disorders. By adding more prebiotic fibre to our diet, we can quickly change the environment in our gut for the better healthy living.
Other Names:
  • Io fibre water
  • Placebo Comparator: Volvic Placebo control Group

    This is the equivalent placebo control water that it is matching the energy values

    Dietary Supplement: Enriched fibre water
    Blend of scientifically substantiated ingredients has been demonstrated to contribute to the reduction of body weight and aid the sustainability of weight loss by providing a healthy, hunger-free weight management system. iofibrewater, makes fibre and gut health simple and refreshing. Each 500 ml bottle of ió fibrewater provides 20%* of your recommended daily fibre intake and 100%* of your daily prebiotic fibre intake with minimal calories and carbohydrates, making us suitable for people on a variety of diets. ió fibrewater is a functional water infused with prebiotic fibre (aka prebiotics), which leads to sub-optimal gut health and often the onset of digestive disorders. By adding more prebiotic fibre to our diet, we can quickly change the environment in our gut for the better healthy living.
    Other Names:
  • Io fibre water
  • Outcome Measures

    Primary Outcome Measures

    1. Anthropometric measurements [Change in body fat percentage from baseline and after 30 days of intervention]

      Body fat percentage

    Secondary Outcome Measures

    1. Blood pressure [Change in blood pressure from baseline and after 30 days of intervention]

      Blood pressure readings

    2. Gastrointestinal symptoms [Change from the baseline in bowel habits including stool frequency and consistency (Bristol stool scale), stomach or intestinal bloating, abdominal pain, incidence and frequency of flatulence]

      Details of bowel habits including stool frequency and consistency (Bristol stool scale), stomach or intestinal bloating, abdominal pain, incidence and frequency of flatulence

    3. Gut microbiota composition [Change in gut microbiota composition from baseline and after 30 days of intervention]

      Details on the gut microbiota composition

    4. Fasting blood glucose via OGGT [Change in plasma blood glucose from baseline and after 30 days of intervention]

      A baseline sample will be take and the participants will be asked to drink 250mL of active or the equivalent placebo water. • The participants will then receive a 50 g glucose drink (orally) in 250ml of water which is commonly used to evaluate pancreatic function and the rate of changes in plasma insulin and glucose (Stumvoll, 2000) and they will donate a total of 7 venous blood samples (up to 5 ml of blood samples at each time point; 30 ml maximum total) at 15, 30, 45, 60, 75, 90, and 120 minutes.

    5. Neurocognitive and Mood Assessment [Changes in Neurocognitive and Mood Assessment from baseline and after 30 days of intervention]

      Neurocognitive and Mood Assessments will take around 60 minutes, but the visits can take up to 120 mins to complete and then will be presented on Qualtrics and Inquisit. Qualtrics is an Experience Management (XM) platform hosted by the university of Roehampton. The exportation of results is only allowed for users who are granted an appropriate account permission, controlled by brand administrators from the university of Roehampton. Qualtrics follows General Data Protection Regulation (GDPR) and comply with applicable data privacy laws. Inquisit is a powerful, easy-to-use psychological measurement and experimentation tool. Inquisit is ideal for lab-based research, cognitive neuroscience, and field testing with laptops. It allows for testing of various cognitive processes including, but not limited to, attention, inhibition, working memory and decision-making.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    • Inclusion criteria
    1. Females and males, aged 18 years to 65 years

    2. BMI ≥25 kg/m2 with any of the following:

    3. IGT (blood glucose level of 7.8-11.0 mmol/L after a 2-hour oral glucose tolerance test (OGTT)), or

    4. IFG (fasting blood glucose level of 5.6-6.9 mmol/L) or

    5. impaired HbA1c (HbA1c level of 5.7%-6.4%)

    6. Not dieting within the last month

    7. not having lost >5% body weight in the previous year

    8. Not increased physical activity levels in the past 2-4 weeks or intending to modify them during the study.

    9. Understands and is willing, able and likely to comply with all study procedures and restriction including being willing to follow the nutritional advice.

    10. Able to eat most everyday foods with no current IBS symptoms.

    11. Habitually consumes three standard meals a day (i.e., breakfast, lunch, and dinner)

    • Exclusion criteria Current use of prescribed medication for neuropsychiatric disorders or history of neuropsychiatric disorders

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Health Sciences Research Centre, Life Sciences Department, University of Roehampton London UK United Kingdom SW15 4JD

    Sponsors and Collaborators

    • University of Roehampton

    Investigators

    • Study Director: Adele Costabile, The University of Roehampton

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    DR ADELE COSTABILE, Associate Professor in Health Sciences and Nutrition, University of Roehampton
    ClinicalTrials.gov Identifier:
    NCT05908474
    Other Study ID Numbers:
    • LSC 23/ 383
    First Posted:
    Jun 18, 2023
    Last Update Posted:
    Jun 18, 2023
    Last Verified:
    Jun 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 18, 2023